When do differences in dissolution profiles predict clinical problems?

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 2, 2007, Pages 111-112

  Ngo, S N T ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CARBAMAZEPINE; CYCLOSPORIN; DIGOXIN; GENERIC DRUG; PHENYTOIN; PROCAINAMIDE; QUINIDINE; WARFARIN;

BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; DRUG SUBSTITUTION; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; NOTE; PRESCRIPTION;

BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DRUGS, GENERIC; GUIDELINES; HUMANS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33947403155     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00807.x     Document Type: Note

References (28)

1. American Academy of Neurology (1990) Assessment: generic substitution for antiepileptic medications. Neurology, 40, 1641-1643.
2. Nuwer MR, Browne TR, Dodson WE et al. (1990) Generic substitutions for antiepileptic drugs. Neurology, 40, 1647-1651.
3. Besag FMC (2000) Is genetic prescribing acceptable in epilepsy? Drug Safety, 23, 173-182.
4. Reiffel JA (2001) Issues in the use of generic antiarrhythmic drugs. Current Opinion in Cardiology, 16, 23-29.
5. Henderson JD, Esham RH (2001) Generic substitution: issues for problematic drugs. Southern Medical Journal, 94, 16-21.
6. Kumet R, Gelenberg AJ (2005) The effectiveness of generic agents in psychopharmacologic treatment. Essential Psychopharmacology, 6, 4-11.
7. Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12, 413-420.
8. Dressman JB, Amidon GL, Reppas C, Shah VP (1998) Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharmaceutical Research, 15, 11-22.
9. Emami J (2006) In vitro-in vivo correlation: from theory to applications. Journal of Pharmacy and Pharmaceutical Sciences, 9, 169-189.
10. Wagner JG, Christensen M, Sakmar E et al. (1973) Equivalence lack in digoxin plasma levels. The Journal of the American Medical Association, 224, 199-204.
11. Lindenbaum J, Butler VP Jr, Murphy JE, Cresswell RM (1973) Correlation of digoxin-tablet dissolution-rate with biological availability. Lancet, 1, 1215-1217.
12. Johnson BF, Greer H, McCrerie J, Bye C, Fowle A (1973) Rate of dissolution of digoxin tablets as a predictor of absorption. Lancet, 1, 1473-1475.
13. Yu LX, Amidon GL, Polli JE et al. (2002) Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceutical Research, 19, 921-925.
14. FDA Office of Generic Drugs (2005) http://www.fda.gov/cder/ogd/, November.
15. Benet LZ, Goyan JE (1995) Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy, 15, 433-440.
16. Wittkowsky AK (1997) Generic warfarin: implications for patient care. Pharmacotherapy, 17, 640-643.
17. Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH (1999) Drug substitution in transplantation: a National Kidney Foundation White Paper. American Journal of Kidney Diseases, 33, 389-397.
18. Benditt DG (1999) Generic antiarrhythmic drugs: what constitutes equivalency. Journal of Interventional Cardiac Electrophysiology, 3, 145-147.
19. Mofsen R, Balter J (2001) Case reports of the re-emergency of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clinical Therapeutics, 23, 1720-1731.
20. Borgheini G (2003) The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clinical Therapeutics, 25, 1578-1592.
21. Grubb BP (1989) Recurrence of ventricular tachycardia after conversion from proprietary to generic procainamide. American Journal of Cardiology, 63, 1532-1533.
22. Ozahowski TP, Greenburg MI, Mock RP (1998) Clinical inequivalence of generic and brand name type IA antiarrhythmic drugs. PACE, 21, 809.
23. Reiffel JA (2000) Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice. The American Journal of Cardiology, 85, 46-52.
24. Reiffel JA, Kowey PR (2000) Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias? The American Journal of Cardiology, 85, 1151-1153.
25. Kahan BD (1999) Considerations concerning generic formulations of immunosuppressive drugs. Transplantation Proceedings, 31, 1635-1641.
26. Vercaigne L, Zhanel G (1998) Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on warfarins. Journal of Pharmacy and Pharmaceutical Sciences, 1, 92-94.
27. GiaQuinto NJ (2000) Are all warfarin preparations alike? A comprehensive overview of current data, emerging opinions, and perspectives. Journal of Thrombosis and Thrombolysis, 9, 139-144.
28. Lee CH, Park YJ, Sands CD, Jones DW, Trang JM (1994) Bioavailability of digoxin tablets in healthy volunteers. Archives of Pharmacal Research, 17, 80-86.